Chengdu Kanghongs' Phase III ophthalmic agent drops 7 points in AMD
Anti-VEGF in 2022: Innovation and Ambition
Emerging Treatments for Neovascular AMD - Retina Today
Anti VEFG Agents In Retinal Diseases
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. - Document - Gale Academic OneFile
Age-Related Macular Degeneration - Retina Research - Retina Associates
Tracking the treatments of tomorrow.
New Drugs in the Pipeline for the Management of AMD | IntechOpen
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. - Document - Gale OneFile: Health and Medicine
Pipeline Report: New entries continue to exceed exits
Anti-VEGF: Where Are We Now?
Emerging Treatments for Neovascular AMD - Retina Today
IJMS | Free Full-Text | Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
Phase III Trials in Wet AMD—What's Next?
The Retina Center
Retinal Physician : October 2019
Full article: Investigational drugs in clinical trials for macular degeneration
panda
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis | SpringerLink
Pipeline Report: Despite major approvals, the queue gets longer
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review
2023: The year of geographic atrophy
Technology name [formulation]* for indication [– first/second/third line]*
